Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
06/30/2021
Revenus
72
64
50
34
13
29
Croissance des revenus (H/H)
20%
28%
47%
162%
-55%
107%
Coût des ventes
10
8
7
5
1
5
Bénéfice brut
61
55
42
28
12
23
Vente, Général et Administration
82
91
65
45
19
37
Recherche et développement
19
20
20
13
7
14
Frais d'exploitation
102
111
84
55
26
49
Autres revenus (charges) non opérationnels
-1
0
8
0
0
0
Bénéfice avant impôts
-48
-61
-35
-26
-14
-26
Charge d'impôt sur le revenu
0
0
0
0
0
0
Bénéfice net
-48
-61
-35
-26
-14
-26
Croissance du bénéfice net
-16%
74%
35%
86%
-46%
-38%
Actions en circulation (diluées)
28.39
25.88
25.33
25
24.91
22.67
Variation des actions (H-H)
9%
2%
1%
0%
10%
12%
EPS (dilué)
-1.71
-2.38
-1.39
-1.07
-0.57
-1.17
Croissance du EPS
-22%
71%
31%
85%
-51%
-43%
Flux de trésorerie libre
-37
-58
-39
-19
-5
-27
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
84.72%
85.93%
84%
82.35%
92.3%
79.31%
Marge opérationnelle
-56.94%
-85.93%
-84%
-79.41%
-107.69%
-89.65%
Marge bénéficiaire
-66.66%
-95.31%
-70%
-76.47%
-107.69%
-89.65%
Marge du flux de trésorerie libre
-51.38%
-90.62%
-78%
-55.88%
-38.46%
-93.1%
EBITDA
-39
-54
-42
-27
-14
-26
Marge EBITDA
-54.16%
-84.37%
-84%
-79.41%
-107.69%
-89.65%
D&A pour le résultat opérationnel
2
1
0
0
0
0
EBIT
-41
-55
-42
-27
-14
-26
Marge EBIT
-56.94%
-85.93%
-84%
-79.41%
-107.69%
-89.65%
Taux d'imposition effectif
0%
0%
0%
0%
0%
0%
Follow-Up Questions
Quels sont les états financiers clés de AVITA Medical Inc ?
Quels sont les ratios financiers clés pour RCEL ?
Comment les revenus de AVITA Medical Inc sont-ils répartis par segment ou géographie ?
AVITA Medical Inc est-elle rentable ?
AVITA Medical Inc a-t-elle des passifs ?
Combien d'actions en circulation AVITA Medical Inc a-t-elle ?
Statistiques clés
Clôture préc.
$3.72
Prix d'ouverture
$3.66
Plage de la journée
$3.52 - $4.43
Plage de 52 semaines
$3.22 - $11
Volume
362.3K
Volume moyen
216.8K
BPA (TTM)
-1.81
Rendement en dividend
--
Capitalisation boursière
$126.8M
Qu’est-ce que RCEL ?
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.